Korea Investment CORP grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 72.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 381,955 shares of the company's stock after buying an additional 159,899 shares during the period. Korea Investment CORP's holdings in Teva Pharmaceutical Industries were worth $8,418,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in TEVA. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $66,000. IFP Advisors Inc lifted its holdings in shares of Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter worth $104,000. Finally, Assetmark Inc. increased its holdings in Teva Pharmaceutical Industries by 1,370.3% in the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company's stock valued at $115,000 after purchasing an additional 4,851 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries Stock Performance
Shares of NYSE TEVA traded up $0.02 during midday trading on Wednesday, reaching $15.31. 7,736,317 shares of the company traded hands, compared to its average volume of 9,703,865. The stock has a 50-day moving average price of $16.95 and a 200 day moving average price of $18.08. The company has a market cap of $17.36 billion, a price-to-earnings ratio of -10.56, a PEG ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Bank of America cut their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Thursday, March 27th. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Finally, Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus target price of $23.43.
View Our Latest Research Report on TEVA
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
